Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.50 |
| ▸ | BRD4 | O60885 | 4/20 | 0.49 |
| ▸ | STAT3 | P40763 | 1/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.48 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.48 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | IL1B | P01584 | 1/20 | 0.47 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25036951 | 0.91 | CRBN (0.52) | CRBNBRD4STAT3ALKMAP1LC3B | |
| SCHEMBL23540399 | 0.88 | CRBN (0.56) | CRBNBRD4STAT3ALKMAP1LC3B | |
| SCHEMBL28881305 | 0.86 | CRBN (0.52) | CRBNBRD4STAT3MAP1LC3BDDB1 | |
| SCHEMBL25037040 | 0.86 | CRBN (0.58) | CRBNBRD4STAT3ALKMAP1LC3B | |
| SCHEMBL20260448 | 0.86 | CRBN (0.58) | CRBNBRD4STAT3MAP1LC3BDDB1 | |
| SCHEMBL23540746 | 0.85 | CRBN (0.56) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL25034759 | 0.85 | CRBN (0.51) | CRBNBRD4MAP1LC3BDDB1IKZF3 | |
| SCHEMBL23540439 | 0.85 | CRBN (0.67) | CRBNSTAT3ALKDDB1 | |
| SCHEMBL30273656 | 0.84 | CRBN (0.58) | CRBNBRD4STAT3ALKMAP1LC3B | |
| SCHEMBL25036892 | 0.83 | CRBN (0.52) | CRBNBRD4STAT3ALKMAP1LC3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383886-A1 | Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof | ABBVIE INC. | 2024-11-21 | — | — | US | disclosed |
| EP-4077319-A1 | PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF | Calico Life Sciences LLC (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2021127586-A1 | PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127586-A1 | PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383886-A1 | Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof | PTPN5, PTPN1, PTPN2 | CRBN 182/4885BRD4 2745/4885STAT3 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.